FDA Approves Impax’s Rytary For Treating Parkinson’s Disease

Impax Pharmaceuticals, a division of Impax Laboratories Inc., Jan. 8 announced that the Food and Drug Administration approved Rytary for treating Parkinson’s disease, post-encephalitic parkinsonism and parkinsonism that may follow carbon monoxide intoxication and/or manganese intoxication.

Rytary is an extended-release oral capsule formulation of carbidopa and levodopa, the company said. The drug shouldn’t be used in patients who are taking nonselective monoamine oxidase (MAO) inhibitors.

“The FDA approval of Rytary is an important new development for the treatment of Parkinson’s disease and provides an extended-release carbidopa-levodopa product that treats Parkinson’s disease,” Fred Wilkinson, president and chief executive officer, Impax Laboratories, ...